Tower Research Capital LLC (Trc) Summit Therapeutics Inc. Transaction History
Tower Research Capital LLC (Trc)
- $3.68 Billion
- Q3 2024
A detailed history of Tower Research Capital LLC (Trc) transactions in Summit Therapeutics Inc. stock. As of the latest transaction made, Tower Research Capital LLC (Trc) holds 1,496 shares of SMMT stock, worth $27,930. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,496
Previous 68,820
97.83%
Holding current value
$27,930
Previous $536,000
94.03%
% of portfolio
0.0%
Previous 0.01%
Shares
16 transactions
Others Institutions Holding SMMT
# of Institutions
192Shares Held
75.8MCall Options Held
2.01MPut Options Held
2.84M-
Baker Bros. Advisors LP New York, NY24.4MShares$456 Million5.73% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.9MShares$204 Million0.0% of portfolio
-
Black Rock Inc. New York, NY7.9MShares$147 Million0.0% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD5.44MShares$102 Million0.01% of portfolio
-
State Street Corp Boston, MA3.47MShares$64.8 Million0.0% of portfolio
About Summit Therapeutics Inc.
- Ticker SMMT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 201,215,008
- Market Cap $3.76B
- Description
- Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecu...